<DOC>
	<DOCNO>NCT00438178</DOCNO>
	<brief_summary>Defects apoptotic process lead onset cancer allow cell grow unchecked oncogneic signal present . Obatoclax design restore apoptosis inhibition Bcl-2 family protein , thereby reinstate natural process cell death often inhibited cancer cell .</brief_summary>
	<brief_title>Safety Efficacy Obatoclax Mesylate ( GX15-070MS ) Treatment Hematological Malignancies</brief_title>
	<detailed_description>This multi-center , open-label , Phase I study obatoclax administer every 2-week weekly cycle , Prolonged Infusion every 2 3 week patient Acute Myeloid Leukemia ( AML ) , Myelodysplastic Syndrome ( MDS ) , Chronic Myeloid Leukemia ( CML ) Myeloid Blast Phase , Myelofibrosis , Previously-Treated Chronic Lymphocytic Leukemia ( CLL ) , Aplastic Anemia . Due PK/PD sample schedule Cycle 1 require overnight hospitalization . For follow cycle treatment may administer outpatient basis discretion investigator . No investigational commercial agent therapy describe within protocol may administer intent treat patient 's malignancy . Supportive care measure include direct control symptom result hematological malignancy allow .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Histologically cytologically confirmation AML , MDS , CML blast phase , myelofibrosis , CLL , aplastic anemia There limitation additional , allowable type amount prior therapy long acute toxicity resolve allowable grade . Must normal organ function Must willing submit blood sampling plan PK PD analyse . Must ability understand willingness sign write informed consent form No agent therapy administer intent treat Uncontrolled , intercurrent illness Pregnant woman woman breast feed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>